Desk workers reported 99.2 hours of weekly screen time, with weekday exposure comprising 93% of waking hours, underscoring ...

A team of University of Michigan investigators reported that their multimodal, chronic disease self-management support program for people living with glaucoma, SEE, was linked to an approximate 20% ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Pitha and colleagues observed a general correlation between patterns of ophthalmic medication and total drug shortage reports in the US. Though ophthalmic drug shortages accounted for 15% of all ...

March is Workplace Eye Awareness Month. The guidelines associated with eye safety in the workplace do not just apply to the general public but to eye care clinicians as well.

In this podcast, Philadelphia cornea and glaucoma surgeon Brian Shafer, MD, discusses the procedures and processes involved ...

Host Deborah Ristvedt, DO, welcomes Trattler to discuss how early inspirations, mentorship, collaboration, and a philosophy ...

Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...

Ocugen has completed enrollment in liMeliGhT, its phase 3 clinical trial of OCU400 for the treatment of retinitis pigmentosa (RP). The company describes liMeliGhT as a 1-year clinical trial that will ...

TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...

Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing durability as a primary unmet need in nAMD and DME management.

The EnVision Summit—billed as the “ultimate gathering place for ophthalmic and optometric professionals”—has come to a close ...